Cain Department of Chemical Engineering
Centennial Celebration Seminar

Mark E. Davis

Nanoparticle-based therapeutics containing either small molecule anti-cancer agents (IT-101; entering Phase II) or siRNA (CALAA-01; in Phase I) are described. The key component in each nanoparticle is a cyclodextrin-containing polymer that endows it with multifunctional behavior. Relationships between nanoparticle design and function in animal models are illustrated. Results from clinical trials are presented so show how nanoparticle-based therapeutics can provide interesting behavior in humans.